Mustang Bio, Inc. (MBIO)
| Market Cap | 13.27M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -62.62M |
| Shares Out | 8.37M |
| EPS (ttm) | -7.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 64,583 |
| Open | 1.47 |
| Previous Close | 1.44 |
| Day's Range | 1.41 - 1.65 |
| 52-Week Range | 1.25 - 11.09 |
| Beta | 1.76 |
| Analysts | Strong Buy |
| Price Target | 19.67 (+1,169.03%) |
| Earnings Date | Nov 14, 2023 |
About MBIO
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare g... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for MBIO stock is "Strong Buy." The 12-month stock price forecast is $19.67, which is an increase of 1,169.03% from the latest price.
News
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cel...
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting
Updated interim data from Mustang's multicenter Phase 1/2 clinical trial demonstrate favorable safety and efficacy profile of MB-106 in heavily pre-treated lymphoma patients Updated interim data from ...
Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WORCESTER, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
WORCESTER, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
MB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical data suppor...
Mustang Bio to Participate in Upcoming September 2023 Investor Conferences
WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in ce...
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
Initial data show clinical responses from four of four indolent lymphoma patients, including complete response in follicular lymphoma patient previously treated with CD19 CAR-T cell therapy
Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cel...
Mustang Bio to Participate in Two August 2023 Investor Conferences
WORCESTER, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cel...
Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences
Transaction and reduction in operating expenses enhance Mustang's cash position Transaction and reduction in operating expenses enhance Mustang's cash position
Mustang Bio Announces Participation in Upcoming Scientific Meetings
Management team to speak at 2nd In Vivo Engineering of Therapeutic Cells Summit and 8th Annual CAR-TCR Summit Management team to speak at 2nd In Vivo Engineering of Therapeutic Cells Summit and 8th An...
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
10 out of 20 patients remain in complete remission for more than a year 95% overall response rate (ORR) and 80% complete response (CR) rate across all patients; 100% ORR and 91% CR with higher dose le...
Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in cohort with durable responses observed; one patient remains in complete remission at 22 months All...
Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates
uBriGene (Boston) Biosciences to acquire Mustang Bio's Worcester manufacturing facility for total consideration of up to $11 million and enters into strategic manufacturing partnership to support MB-1...
Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., May 12, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell...
Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy
Data from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023 Outpatient treatment of follicular lymphoma selected for oral presentation at ICML WORCESTER, Mass., May 11, ...
Mustang Bio Announces Reverse Stock Split
WORCESTER, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical br...
Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in ce...
Mustang Bio to Participate in Cantor's The Future of Oncology Virtual Symposium
WORCESTER, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical br...
Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference
WORCESTER, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical bre...
Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones
MB-106 clinical trial under Mustang's IND continues to enroll patients
Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cel...
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia
MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia
Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Enrollment continues in clinical trial of MB-106 under Mustang's IND; next data disclosure anticipated 4Q 2022
Mustang Bio to Participate in Upcoming September 2022 Investor Conferences
WORCESTER, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in ce...